Register for the
COVID-19 Treatments and Vaccine Rollout session
Thursday, December 17, 2020 at 3:00 PM Est
COVID-19 Treatments and Vaccine Rollout
One of the most important milestones to return to normal after the COVID-19 pandemic is the development, approval and distribution of a vaccine. Both Pfizer (an NHCSL Business Board Member) and Moderna have requested emergency FDA authorization of 95%-effective vaccines they have developed. The Pfizer clinical trials actively sought to include people of color. Some vaccine candidates require extreme refrigeration at -70 degrees Celsius (-94o F), which will impact their distribution, and potentially require reformulation before widespread use. Priority vaccine distribution determinations are ongoing.
Equally important is the development, approval and availability of treatments. The world urgently needs medicines that can help reduce the impact of COVID-19 while the global scientific community works toward an eventual vaccine. Eli Lilly and Company (another NHCSL Business Board Member) is studying the world’s first therapies specifically designed to treat COVID-19 — antibodies engineered for their potential to neutralize, and potentially treat, the disease. In addition to antibodies, Lilly medicines are being studied to understand their potential in treating complications of COVID-19. And, they are engaging global regulators regarding emergency-use authorization (EUA) for these treatments, which was recently granted by the U.S. FDA for two different therapies. This session will discuss all those aspects of the ongoing pandemic as well as the human resources impact of vaccines and treatments.
Dr. Aliza Lifshitz, Editorial Director, Vida y Salud
Dr. Alejandro Cané, North America Chief of Scientific and Medical Affairs, Vaccines Division, Pfizer
Dr. Carlos O Garner, Vice President, Global Regulatory Affairs, Eli Lilly and Company
VADM Jerome M. Adams, M.D., M.P.H., U.S. Surgeon General
Senator Daniel A. Ivey-Soto (NM), President, NHCSL